Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 9/20 | 0.60 |
| ▸ | GSK3B | P49841 | 9/20 | 0.60 |
| ▸ | DYRK1A | Q13627 | 9/20 | 0.60 |
| ▸ | CSNK1D | P48730 | 8/20 | 0.60 |
| ▸ | AURKB | Q96GD4 | 8/20 | 0.60 |
| ▸ | CDK1 | P06493 | 8/20 | 0.60 |
| ▸ | PIM1 | P11309 | 8/20 | 0.60 |
| ▸ | CDK2 | P24941 | 8/20 | 0.60 |
| ▸ | PLK4 | O00444 | 7/20 | 0.60 |
| ▸ | DAPK3 | O43293 | 7/20 | 0.60 |
| ▸ | CHEK2 | O96017 | 7/20 | 0.60 |
| ▸ | MAPK9 | P45984 | 7/20 | 0.60 |
| ▸ | PLK3 | Q9H4B4 | 7/20 | 0.60 |
| ▸ | AURKA | O14965 | 6/20 | 0.60 |
| ▸ | PRKACA | P17612 | 6/20 | 0.60 |
| ▸ | SGK2 | Q9HBY8 | 6/20 | 0.60 |
| ▸ | CSNK2A1 | P68400 | 5/20 | 0.60 |
| ▸ | PIM2 | Q9P1W9 | 5/20 | 0.60 |
| ▸ | RPS6KA3 | P51812 | 5/20 | 0.60 |
| ▸ | KDR | P35968 | 6/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29069393 | 0.84 | ICAM1 (0.69) | GSK3AGSK3BDYRK1ACSNK1DAURKB | |
| SCHEMBL30744198 | 0.83 | CSNK1D (0.63) | GSK3AGSK3BDYRK1ACSNK1DAURKB | |
| SCHEMBL660155 | 0.83 | CSNK1D (0.63) | GSK3AGSK3BDYRK1ACSNK1DAURKB | |
| SCHEMBL24721595 | 0.81 | PLK4 (0.59) | GSK3AGSK3BDYRK1ACSNK1DAURKB | |
| SCHEMBL15910879 | 0.81 | PIM1 (0.59) | GSK3AGSK3BDYRK1ACSNK1DAURKB | |
| SCHEMBL658705 | 0.81 | ICAM1 (0.73) | GSK3AGSK3BDYRK1ACSNK1DAURKB | |
| SCHEMBL7934399 | 0.79 | GSK3A (0.78) | GSK3AGSK3BDYRK1ACSNK1DAURKB | |
| SCHEMBL5555028 | 0.78 | CSNK1D (0.48) | GSK3AGSK3BDYRK1ACSNK1DAURKB | |
| SCHEMBL5550116 | 0.77 | DAPK3 (0.55) | GSK3AGSK3BDYRK1ACSNK1DAURKB | |
| SCHEMBL7619323 | 0.76 | GSK3A (1.00) | GSK3AGSK3BDYRK1ACSNK1DAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119465114-A | Nickel plating solution on tungsten-based ceramic and chemical plating process thereof | 江苏矽智半导体科技有限公司 | 2025-02-18 | — | — | CN | claimed |
| CN-119465114-A | Nickel plating solution on tungsten-based ceramic and chemical plating process thereof | 江苏矽智半导体科技有限公司 | 2025-02-18 | — | — | CN | disclosed |
| CN-118702627-A | CD73 small molecule inhibitor, pharmaceutical composition and application thereof | 深圳市新樾生物科技有限公司 | 2024-09-27 | — | — | CN | disclosed |
| CN-116730995-B | Hydrazide compound, preparation method and application thereof | 深圳微芯生物科技股份有限公司 | 2024-06-25 | — | — | CN | disclosed |
| CN-112979675-B | Small molecular sulfur-containing heterocyclic compound | 维眸生物科技（上海）有限公司 | 2023-12-19 | — | — | CN | disclosed |
| CN-116730995-A | Hydrazide compound, preparation method and application thereof | 深圳微芯生物科技股份有限公司 | 2023-09-12 | — | — | CN | disclosed |
| CN-112979675-A | Small-molecule sulfur-containing heterocyclic compound | 维眸生物科技（上海）有限公司 | 2021-06-18 | — | — | CN | disclosed |
| WO-2021115495-A1 | SMALL-MOLECULE SULFUR-CONTAINING HETEROCYCLIC COMPOUND | 维眸生物科技（上海）有限公司 | 2021-06-17 | — | — | WO | disclosed |
| WO-2021115495-A1 | SMALL-MOLECULE SULFUR-CONTAINING HETEROCYCLIC COMPOUND | 维眸生物科技（上海）有限公司 | 2021-06-17 | — | — | WO | disclosed |
| US-8378104-B2 | 7-aminofuropyridine derivatives | OSI Pharmaceuticals, LLC (US) | 2013-02-19 | — | — | US | disclosed |
| EP-2534156-A1 | 7-AMINOFUROPYRIDINE DERIVATIVES | OSI Pharmaceuticals, LLC (US) | 2012-12-19 | — | — | EP | disclosed |
| US-20120046267-A1 | 7-AMINOFUROPYRIDINE DERIVATIVES | OSI PHARMACEUTICALS, INC. | 2012-02-23 | — | — | US | disclosed |
| WO-2011100502-A1 | 7-AMINOFUROPYRIDINE DERIVATIVES | OSI Pharmaceuticals, LLC (US) | 2011-08-18 | — | — | WO | disclosed |
| EP-1753428-A2 | KINASE INHIBITORS AS THERAPEUTIC AGENTS | Abbott Laboratories (US) | 2007-02-21 | — | — | EP | disclosed |
| US-20060074102-A1 | Kinase inhibitors as therapeutic agents | ABBOTT LABORATORIES | 2006-04-06 | — | — | US | disclosed |
| WO-2005110410-A2 | KINASE INHIBITORS AS THERAPEUTIC AGENTS | ABBOTT LABORATORIES (US) | 2005-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074102-A1 | Kinase inhibitors as therapeutic agents | ABL1, MAP3K19, MAP3K20 | GSK3A 453/4885GSK3B 462/4885DYRK1A 498/4885 |
| US-20120046267-A1 | 7-AMINOFUROPYRIDINE DERIVATIVES | MAP3K5, STK17A, MAPKAPK5 | GSK3A 581/4885GSK3B 393/4885DYRK1A 2154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.